PL2776430T3 - Pochodne 2-(1,2,3-triazol-2-ilo)benzamidu i 3-(1,2,3-triazol-2-ilo)pikolinoamidu jako antagoniści receptora oreksynowego - Google Patents

Pochodne 2-(1,2,3-triazol-2-ilo)benzamidu i 3-(1,2,3-triazol-2-ilo)pikolinoamidu jako antagoniści receptora oreksynowego

Info

Publication number
PL2776430T3
PL2776430T3 PL12791862.1T PL12791862T PL2776430T3 PL 2776430 T3 PL2776430 T3 PL 2776430T3 PL 12791862 T PL12791862 T PL 12791862T PL 2776430 T3 PL2776430 T3 PL 2776430T3
Authority
PL
Poland
Prior art keywords
triazol
benzamide
receptor antagonists
orexin receptor
picolinamide derivatives
Prior art date
Application number
PL12791862.1T
Other languages
English (en)
Polish (pl)
Inventor
Martin Bolli
Christoph Boss
Christine Brotschi
Bibia Heidmann
Thierry Sifferlen
Jodi T. Williams
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2776430T3 publication Critical patent/PL2776430T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL12791862.1T 2011-11-08 2012-11-07 Pochodne 2-(1,2,3-triazol-2-ilo)benzamidu i 3-(1,2,3-triazol-2-ilo)pikolinoamidu jako antagoniści receptora oreksynowego PL2776430T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2011054976 2011-11-08

Publications (1)

Publication Number Publication Date
PL2776430T3 true PL2776430T3 (pl) 2016-09-30

Family

ID=47258050

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12791862.1T PL2776430T3 (pl) 2011-11-08 2012-11-07 Pochodne 2-(1,2,3-triazol-2-ilo)benzamidu i 3-(1,2,3-triazol-2-ilo)pikolinoamidu jako antagoniści receptora oreksynowego

Country Status (28)

Country Link
US (1) US9150566B2 (enExample)
EP (1) EP2776430B1 (enExample)
JP (1) JP5718535B2 (enExample)
KR (1) KR101676930B1 (enExample)
CN (1) CN103917538B (enExample)
AR (1) AR088692A1 (enExample)
AU (1) AU2012335194B2 (enExample)
BR (1) BR112014010617B1 (enExample)
CA (1) CA2846568C (enExample)
CL (1) CL2014000659A1 (enExample)
CY (1) CY1117638T1 (enExample)
DK (1) DK2776430T3 (enExample)
EA (1) EA024106B1 (enExample)
ES (1) ES2572703T3 (enExample)
HR (1) HRP20160678T1 (enExample)
HU (1) HUE029239T2 (enExample)
IL (1) IL232462A (enExample)
IN (1) IN2014CN04127A (enExample)
MX (1) MX343837B (enExample)
MY (1) MY167791A (enExample)
PH (1) PH12014500852A1 (enExample)
PL (1) PL2776430T3 (enExample)
SG (1) SG11201401665WA (enExample)
SI (1) SI2776430T1 (enExample)
TW (2) TWI565703B (enExample)
UA (1) UA112317C2 (enExample)
WO (1) WO2013068935A1 (enExample)
ZA (1) ZA201404189B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
EP2811997B1 (en) 2012-02-07 2018-04-11 Eolas Therapeutics Inc. Substituted prolines/piperidines as orexin receptor antagonists
LT2855453T (lt) 2012-06-04 2017-02-27 Actelion Pharmaceuticals Ltd. Benzimidazolo prolino dariniai
EP2970241A1 (en) 2013-03-12 2016-01-20 Actelion Pharmaceuticals Ltd. Azetidine amide derivatives as orexin receptor antagonists
PT3077389T (pt) 2013-12-03 2017-12-15 Idorsia Pharmaceuticals Ltd Forma cristalina de (s)-(2-(6-cloro-7-metil-1hbenzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona e a sua utilização como como antagonistas do receptor de orexina
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
SI3077391T1 (sl) 2013-12-04 2018-11-30 Idorsia Pharmaceuticals Ltd Uporaba benzimidazol-prolinskih derivatov
WO2015087853A1 (ja) * 2013-12-13 2015-06-18 大正製薬株式会社 オキサジナン化合物の結晶形及びその製造方法
JP2017024990A (ja) * 2013-12-13 2017-02-02 大正製薬株式会社 オキサゾリジン及びオキサジナン誘導体
WO2015174532A1 (ja) * 2014-05-16 2015-11-19 国立大学法人 東京大学 うつ治療剤
WO2016025669A1 (en) 2014-08-13 2016-02-18 Eolas Therapeutics, Inc. Difluoropyrrolidines as orexin receptor modulators
WO2016095205A1 (en) * 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. Heteroaryl orexin receptor antagonists
CN104557744B (zh) * 2014-12-23 2017-04-12 广东东阳光药业有限公司 一种三氮唑化合物的制备方法
WO2017088759A1 (en) 2015-11-23 2017-06-01 Sunshine Lake Pharma Co., Ltd. OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF
PL3414241T3 (pl) 2016-02-12 2022-10-03 Astrazeneca Ab Piperydyny podstawione halo jako modulatory receptora oreksyny
EP3619199B1 (en) 2017-05-03 2021-07-07 Idorsia Pharmaceuticals Ltd Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives
WO2020099511A1 (en) * 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
GB201901142D0 (en) 2019-01-28 2019-03-20 Heptares Therapeutics Ltd OX1 Antagonists
WO2022167330A1 (en) 2021-02-02 2022-08-11 Idorsia Pharmaceuticals Ltd A crystalline form of (4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(r)-3-(3-[1,2,3]triazol-2-yl-benzyl)-morpholin-4-yl]-methanone
TW202400149A (zh) * 2022-05-13 2024-01-01 瑞士商愛杜西亞製藥有限公司 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物
CN115947697A (zh) * 2022-12-28 2023-04-11 苏州汉德创宏生化科技有限公司 一种3-氧代吗啉-4-羧酸叔丁酯的合成方法
CN121057722A (zh) * 2023-04-10 2025-12-02 三菱瓦斯化学株式会社 化合物、组合物、显现增敏效果的方法和制造方法
GB202311280D0 (en) 2023-07-21 2023-09-06 Bial Portela & Ca Sa Orexin receptor antagonists
GB202311281D0 (en) 2023-07-21 2023-09-06 Bial Portela & Ca Sa Orexin receptor antagonists

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130432A (en) 1990-12-21 1992-07-14 Syntex (U.S.A.) Inc. Process for preparing cyclic amines and intermediate products thereof
EP0591426A4 (en) 1991-06-27 1996-08-21 Univ Virginia Commonwealth Sigma receptor ligands and the use thereof
JP2004534026A (ja) 2001-05-05 2004-11-11 スミスクライン ビーチャム パブリック リミテッド カンパニー オレキシン受容体アンタゴニストとしてのn−アロイルサイクリックアミン誘導体
PL367677A1 (en) 2001-06-28 2005-03-07 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0124463D0 (en) * 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
HRP20150371T1 (hr) 2004-03-01 2015-05-08 Actelion Pharmaceuticals Ltd. Supstituirani derivati 1,2,3,4-tetrahidroizokinolina
AU2007226203A1 (en) 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Tetrahydroisoquinoline derivatives to enhance memory function
US8618102B2 (en) 2006-07-14 2013-12-31 Merck Sharp & Dohme Corp. Bridged diazepan orexin receptor antagonists
GB0620818D0 (en) 2006-10-19 2006-11-29 Ucb Sa Therapeutic agents
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
EP2207778A2 (en) 2007-09-24 2010-07-21 Actelion Pharmaceuticals Ltd. Pyrrolidines and piperidines as orexin receptor antagonists
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
WO2010048010A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
WO2010048013A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted morpholine orexin receptor antagonists
JP2012506375A (ja) 2008-10-21 2012-03-15 メルク・シャープ・エンド・ドーム・コーポレイション 2,5−二置換ピペリジンオレキシン受容体アンタゴニスト
UY32277A (es) 2008-12-02 2010-05-31 Glaxo Group Ltd Derivados de n-{[1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4.1.0-il}metil}-2heteroarilamina y uso de los mismos
BRPI0922353A2 (pt) 2008-12-02 2018-06-05 Glaxo Group Ltd Derivados de n-{[(1r,4s, 6r-3- (2-piridinilcarbonil) - 3azabiciclo [4.1.0] hept-4-il] metil}-2-heteroarilamina e usos dos mesmos
WO2011050200A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
JP5848251B2 (ja) 2009-10-23 2016-01-27 ヤンセン ファーマシューティカ エヌ.ベー. オレキシン受容体調節因子としての縮合複素環式化合物
DK3093291T3 (da) 2009-10-23 2019-07-29 Janssen Pharmaceutica Nv Disubstituerede octahy-dropyrrolo [3,4-c]pyrroler som orexinreceptormodulatorer

Also Published As

Publication number Publication date
NZ625896A (en) 2016-04-29
WO2013068935A1 (en) 2013-05-16
EA201400553A1 (ru) 2014-10-30
TWI565703B (zh) 2017-01-11
BR112014010617A2 (pt) 2017-04-25
HRP20160678T1 (hr) 2016-07-15
PH12014500852A1 (en) 2016-03-02
HUE029239T2 (en) 2017-02-28
AR088692A1 (es) 2014-06-25
JP2014532753A (ja) 2014-12-08
ZA201404189B (en) 2017-08-30
EA024106B1 (ru) 2016-08-31
CN103917538A (zh) 2014-07-09
SI2776430T1 (sl) 2016-06-30
IN2014CN04127A (enExample) 2015-07-10
TW201632517A (zh) 2016-09-16
CN103917538B (zh) 2016-08-24
CY1117638T1 (el) 2017-04-26
MX343837B (es) 2016-11-24
MX2014005635A (es) 2014-06-23
CL2014000659A1 (es) 2014-08-18
BR112014010617A8 (pt) 2017-12-26
BR112014010617B1 (pt) 2021-12-14
AU2012335194B2 (en) 2017-05-25
KR20140096338A (ko) 2014-08-05
JP5718535B2 (ja) 2015-05-13
EP2776430B1 (en) 2016-03-16
DK2776430T3 (en) 2016-05-09
SG11201401665WA (en) 2014-09-26
EP2776430A1 (en) 2014-09-17
ES2572703T3 (es) 2016-06-01
AU2012335194A1 (en) 2014-07-03
US20150158855A1 (en) 2015-06-11
TW201323421A (zh) 2013-06-16
CA2846568C (en) 2020-01-14
HK1199022A1 (zh) 2015-06-19
IL232462A (en) 2016-11-30
MY167791A (en) 2018-09-26
TWI555747B (zh) 2016-11-01
KR101676930B1 (ko) 2016-11-16
IL232462A0 (en) 2014-06-30
UA112317C2 (uk) 2016-08-25
CA2846568A1 (en) 2013-05-16
US9150566B2 (en) 2015-10-06

Similar Documents

Publication Publication Date Title
ZA201404189B (en) 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists
AP3613A (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 abl1abl2 bcr-abl1
EP2934517A4 (en) 2-PYRIDYLOXY-3-NITRIL-4-SUBSTITUTED OREXINE RECEPTOR ANTAGONISTS
PT2785181T (pt) Compostos 2-(fenil substituído)-ciclopentano-1,3-diona, e seus derivados
SMT201700141T1 (it) Composti di 1,3-ossazolidina o 1,3-ossazinano come antagonisti dei recettori dell'orexina
ZA201406085B (en) Heterocyclic amide derivatives as p2x7 receptor antagonists
IL220851A (en) Process for the preparation of n - (2 - (2 - (4 - (2 - (7,6-dimethoxy-4,3-dihydro-iso-quinoline-2 - (1 h))) ethyl) phenyl) - h2 - tetrazole - 5-ram (5,4-dimethoxyphenyl) -4-oxo-h4-chromium-2-carboxamide methane-sulfonate, its intermediate and intermediate preparation process
PT2935227T (pt) Amidas diazol como antagonistas do recetor ccr1
ZA201405959B (en) Novel neurokinin 1 receptor antagonist compounds
EP2771346A4 (en) ISOXAZOLOPYRIDIN-orexin
ZA201504521B (en) Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same
SI2864291T1 (sl) N-(4-(kinolin-4-iloksi)cikloheksil(metil))(hetero)arilkarboksamidi kot antagonisti receptorja androgena, njihova izdelava in uporaba kot medicinski izdelki
IL241743A0 (en) Non-competitive nicotinic receptor antagonists
IL238829A0 (en) Process for the preparation of 4-(cyclopropylmethoxy-3,5)-n-(dichloro-1-oxido-4-pyridyl)-5-methoxypyridine-2-carboxamide
IL230334A0 (en) Non-competitive nicotinic receptor antagonists